testing tech

Houston developer to roll out innovative pilot to improve parking at major development

Redemption Square in Generation Park will feature high-tech parking solution pilot program. Photo via generationpark.com

Houston real estate company McCord Development will roll out an innovative 12-week pilot to learn how to make parking smarter at its master planned development Generation Park in Northeast Houston.

In partnership with Milwaukee-based CivicSmart Inc., a leader in Smart City parking, the company will test a new Internet-of-Things-based parking solution at Generation Park's mixed-use lifestyle center, Redemption Square. The program is only the second of its kind in the U.S., according to McCord.

McCord will install 30 of CivicSmart's solar powered bollards at Redemption Square that track real-time parking occupancy data through LTE license-plate-reading cameras. The data will be analyzed to help McCord optimize traffic and develop better strategies and parking rates.

"We are thrilled to introduce one of the first parking pilot programs in the country,” Ashwin Chandran, Director of Technology Innovation at McCord, said in a statement. “At McCord, we strive to measure and understand behavior in order to enhance the human experience and make efficient business decisions. We hope to use this data to improve the overall performance of our operations across all our assets.”

According to the statement, the intention of the program is to help keep curbside spots available for short-term guests.

From the customer perspective, parkers will pay via text or QR code, where they will enter their license plate number and payment information, which will be stored for subsequent visits.

The bollards can also dispatch up-to-the-minute pricing details to parkers, and can be controlled remotely by the developer to close certain parking spots for special events.

In addition to the 30 bollards, Redemption Square will still also offer free parking in its nearby garage, and other parking options on Redemption Square Road and metered spaces on Assay Street, according to the statement.

Last week, McCord also announced plans to create a 45-acre biomanufacturing campus within the 4,300-acre Generation Park development. Known as BioHub Two, the center will include 500,000 square feet for manufacturing, lab, and office space. It's slated to join San Jacinto College’s Biotech Training Center in the development, which was announced last December.

Other plans for Generation Park include two multifamily complexes, a mixed-use development called The Commons, and retail and green spaces.

McCord will install 30 of CivicSmart's solar powered bollards at Redemption Square that track real-time parking occupancy data through LTE license-plate-reading cameras. Photo courtesy of Generation Park

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted